← Back to Search

Mobile Health Messaging for HIV/AIDS

N/A
Recruiting
Led By Lunthita M Duthely, Ed.D.
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female >= 18 years old at enrollment
Be older than 18 years old
Must not have
Women who are cognitively impaired or are not able to consent for themselves
Adolescents < 18 years old at enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 12
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new mobile health system that sends text reminders to HIV+ women to help them stick to their treatment plan. The system will also address individual barriers to care, like stigma and mistrust.

Who is the study for?
This trial is for women over 18 with HIV who have missed appointments, had a detectable viral load, or haven't taken their meds as prescribed. They must be currently in care or recently back in care and own a working cell phone. It's not for men, those under 18, cognitively impaired individuals unable to consent, or without a cell phone.
What is being tested?
The study is testing an mHealth system that sends text messages to help women with HIV stick to their treatment plans. The goal is to see if this method helps patients keep up with appointments, refill prescriptions on time, take medication regularly and overcome barriers like stigma.
What are the potential side effects?
Since the intervention involves mobile health messaging rather than medication or medical procedures, there are no direct physical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 18 or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to make medical decisions for myself due to cognitive impairment.
Select...
I am under 18 years old.
Select...
I am a man.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability of the mHealth application
Rate of Enrollment
Secondary study objectives
Change in Clinic Attendance
Change in HIV Stigma
Change in Medical Mistrust
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Mobile Health Messaging ArmExperimental Treatment2 Interventions
The Patient Navigation and Mobile Health Messaging Arm will receive standard of care, as well as patient navigation assistance and the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
Group II: Control ArmActive Control1 Intervention
The control arm will receive standard of care.
Group III: Focus Group ArmActive Control1 Intervention
The results of the focus groups will contribute to the wording and design of the intervention.

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor
955 Previous Clinical Trials
428,773 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,605 Previous Clinical Trials
3,329,838 Total Patients Enrolled
Lunthita M Duthely, Ed.D.Principal InvestigatorUniversity of Miami
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Mobile Health Messaging application Clinical Trial Eligibility Overview. Trial Name: NCT03738410 — N/A
HIV/AIDS Research Study Groups: Control Arm, Mobile Health Messaging Arm, Focus Group Arm
HIV/AIDS Clinical Trial 2023: Mobile Health Messaging application Highlights & Side Effects. Trial Name: NCT03738410 — N/A
Mobile Health Messaging application 2023 Treatment Timeline for Medical Study. Trial Name: NCT03738410 — N/A
~9 spots leftby Apr 2025